Blinklab Limited (AU:BB1) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BlinkLab Limited has announced promising results from a large-scale study validating its smartphone-based diagnostic tool, BlinkLab Dx 1, which showed 91% sensitivity and 85% specificity in detecting autism in children. This breakthrough positions BlinkLab’s technology as a potential game-changer in the autism diagnostics market, addressing the high demand and long wait times for assessments. The study underlines the effectiveness of non-invasive digital biomarkers and highlights BlinkLab’s innovative use of AI and machine learning in healthcare.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.